Abstract 281P
Background
Based on Globocan 2020, prostate cancer is the second most common male cancer worldwide. One of the main treatments for localized prostate cancer patients is definitive radiotherapy. Regarding limited access to intensity modulated radiation therapy and other modern techniques in developing countries, most patients in these countries are still being treated with 3D conformal RT techniques. Considering the fact that there is association between local control and prostate cancer specific mortality, we aimed to investigate the local control in unfavorable intermediate and high risk prostate cancer patients whom underwent definitive radiotherapy with 3D conformal technique.
Methods
50 patients involved in this study. They all were treated by definitive radiotherapy with 3D conformal technique since 2014 in the Radiation Department of Hamadan University of Medical Sciences. The required data was collected through the assessment of patient's' medical records. All patients were treated using a 4-field (Box) 3D technique with a total dose of 70 Gy. Additionally, in all patients, the whole pelvis was covered in the initial phase of treatment (46Gy).
Results
After the median follow up of 45 month 13 treatment failure was seen in the study population. Bio-chemical relapse occurred in 13 patients (26%). Seven patients were found to have local recurrences (14%). Distant failure, all in bone, occurred in 6 patients (12%). The 3year BCR free survival, local failure free survival and metastases free survival were 76%, 88%, and 88% respectively. The most important factor for BCR, distant failure, and overall failure was extension of disease (T stage).
Conclusions
Our results were lower compared to the results announced in the developed countries' center. This indicates that the use of modern radiotherapy techniques has been essential in prostate cancer treatment, both due to the increased treatment effectiveness and the reduction of treatment side effects. It is vital for developing countries to plan their health care policies in a way that improves patients' access to these innovative techniques. And governments should allocate a budget for updating radiotherapy devices in their country's infrastructure planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Bayani.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract